Bausch Health Companies Inc. Stock News

Today, Bausch Health Company acknowledged the FDA's decision to tentatively approve a generic version of Xifaxan. The company also noted that final approval remains off the table until Oct. 2, 2029.

Bausch (BHC) obtains a positive ruling for one of its top drugs, Xifaxan, against Norwich from the U.S. District Court of Delaware. Stock up in response to the same.

Bausch Health Cos. Inc. BHC, +24.09% on Wednesday said a U.S. district court stuck with an earlier judgment that prevented an application for a rival generic version of its Xifaxan irritable bowel syn

Kevin Kelly, Kelly Intelligence CEO, joins CNBC's Melissa Lee and the Options Action traders to discuss bullish bets on Bausch Health.

Bausch could get to keep its patent for an IBS drug for another six years. The drug brought in nearly $400 million in the first quarter.

Bausch Health has been through rough times, leading to skepticism among investors. Its investment potential, however, has been on the upswing since 2016, when Joseph Papa took over as CEO.

Bausch (BHC) declines as it misses on earnings and sales in the first quarter.

The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates

LAVAL, QC / ACCESSWIRE / April 13, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its first-quarter financial results on Thursday, May 4, 2023. Bausch Health will host a conferen

Bausch + Lomb Corporation recently appointed a new high-profile CEO in Brent Saunders. Bausch Health Companies Inc. has hit the internal metrics necessary to justify spinning off more Bausch + Lomb sh

Bausch (BHC) reports an increase in earnings and sales in the fourth quarter as the company???s business revives in the second half.

Bausch + Lomb Corp. BLCO, -2.01% said Wednesday it had a loss of $1 million, or breakeven on a per-share basis, for the fourth quarter, after earnings of $51 million, or 15 cents a share, in the year-

Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Bausch + Lomb Corp. BLCO, +1.31% said Wednesday it has named Brent Saunders as chief executive and chair effective March 6. Saunders, who will return to the company he headed from 2010 to 2013, will r

LAVAL, QC / ACCESSWIRE / February 1, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its fourth-quarter and full-year financial results on Thursday, Feb. 23, 2022. Bausch Health w